American Society of Hematology: Oral Agent Beats Enoxaparin, May Aid Outpatient DVT Tx
MedPageToday -- ORLANDO -- The oral factor Xa inhibitor rivaroxaban (Xarelto) reduced the risk of recurrent venous thromboembolism (VTE) with no increase in bleeding, according to results of two large clinical trials reported here.